Multiple roles for MMPs and TIMPs in cerebral ischemia

GLIA

Volumn 50, Issue 4, 2005, Pages 329-339

  Cunningham, Lee Anna ^a   Wetzel, Monica ^a   Rosenberg, Gary A ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Blood brain barrier; Fas; Metalloproteinase neurotrophin; Stroke; VEGF

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN INJURY; BRAIN ISCHEMIA; ENZYME ACTIVITY; HOMEOSTASIS; HUMAN; NERVE CELL NECROSIS; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BRAIN ISCHEMIA; CELL DEATH; HUMANS; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 20344373695     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.20169     Document Type: Review

References (115)

1. Aoki T, Sumii T, Mori T, Wang X, Lo EH. 2002. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury. Mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33:2711-2717.
2. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH, Banda MJ. 1990. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50:2322-2329.
3. Apte SS, Hayashi K, Seldin MF, Mattei MG, Hayashi M, Olsen BR. 1994a. Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn 200:177-197.
4. Apte SS, Mattei MG, Olsen BR. 1994b. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 19:86-90.
5. Apte SS, Olsen BR, Murphy G. 1995. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family [published erratum appears in J Biol Chem 271:2874, 1996]. J Biol Chem 270:14313-14318.
6. Arai K, Lee SR, Lo EH. 2003. Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia 43:254-264.
7. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. 2000. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681-1689.
8. Asahi M, Sumii T, Fini ME, Itohara S, Lo EH. 2001a. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. NeuroReport 12:3003-3007.
9. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH. 2001b. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732.
10. Ashkenazi A, Dixit VM. 1998. Death receptors: signaling and modulation. Science 281:1305-1308.
11. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. 1996. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16:7910-7919.
12. Baker AH, Edwards DR, Murphy G. 2002. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719-3727.
13. Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2:737-744.
14. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. 1999. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 55:639-652.
15. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267-283.
16. Chang C, Werb Z. 2001. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11:S37-43.
17. Chang DI, Hosomi N, Lucero J, Heo JH, Abumiya T, Mazar AP, del Zoppo GJ. 2003. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab 23:1408-1419.
18. Conant K, Haughey N, Nath A, St. Hillaire C, Gary DS, Pardo CA, Wahl LM, Bilak M, Milward E, Mattson MP. 2002. Matrix metalloproteinase-1 activates a pertussis toxin-sensitive signaling pathway that stimulates the release of matrix metalloproteinase-9. J Neurochem 82:885-893.
19. Conant K, St Hillaire C, Nagase H, Visse R, Gary D, Haughey N, Anderson C, Turchan J, Nath A. 2004. Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt. J Biol Chem 279:8056-8062.
20. Cross AK, Woodroofe MN. 1999. Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia 28:183-189.
21. Deb S, Wenjun Zhang J, Gottschall PE. 2003. Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res 970:205-213.
22. Dirnagl U, Iadecola C, Moskowitz MA. 1999. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391-397.
23. Dzwonek J, Rylski M, Kaczmarek L. 2004. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 567:129-135.
24. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
25. Felderhoff-Mueser U, Taylor DL, Greenwood K, Kozma M, Stibenz D, Joashi UC, Edwards AD, Mehmet H. 2000. Fas/CD95/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is upregulated following cerebral hypoxic-ischemic injury to the developing rat brain. Brain Pathol 10:17-29.
26. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Nagase H. 1995. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res 6:255-263.
27. Fowlkes JL, Serra DM, Nagase H, Thrailkill KM. 1999. MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth. Ann N Y Acad Sci 878:696-699.
28. Fowlkes JL, Serra DM, Bunn RC, Thrailkill KM, Enghild JJ, Nagase H. 2004. Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes. Endocrinology 145:620-626.
29. Frolichsthal-Schoeller P, Vescovi AL, Krekoski CA, Murphy G, Edwards DR, Forsyth P. 1999. Expression and modulation of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinases in human embryonic CNS stem cells. Neuro Report 10:345-351.
30. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. 1998. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539-1550.
31. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. 2001. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21:1393-1400.
32. Gottschall PE, Deb S. 1996. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 3:69-75.
33. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA. 2002. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297:1186-1190.
34. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, Wang X, Rosenberg GA; Lo EH; Moskowitz MA. 2004. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113:1447-1455.
35. Hamann GF, del Zoppo GJ, von Kummer R. 1999. Hemorrhagic transformation of cerebral infarction-possible mechanisms. Thromb Haemost 82(suppl 1):92-94.
36. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. 1995. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26:2120-2126.
37. Hamann GF, Okada Y, del Zoppo GJ. 1996. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 16:1373-1378.
38. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
39. Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN. 2000. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 123(Pt 4):698-709.
40. Harrington AW, Leiner B, Blechschmitt C, Arevalo JC, Lee R, Morl K, Meyer M, Hempstead BL, Yoon SO, Giehl KM. 2004. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci USA 101:6226-6230.
41. Hayashita-Kinoh H, Kinoh H, Okada A, Komori K, Itoh Y, Chiba T, Kajita M, Yana I, Seiki M. 2001. Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth. Cell Growth Differ 12:573-580.
42. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z. 2003. Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 10:136-141.
43. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. 1999. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19:624-633.
44. Higashi S, Miyazaki K. 2003. Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. Biochemistry 42:6514-6526.
45. Ibanez CF. 2002. Jekyll-Hyde neurotrophins: the story of proNGF. Trends Neurosci 25:284-286.
46. Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P. 1999. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest 79:417-425.
47. Johnston JB, Zhang K, Silva C, Shalinsky DR, Conant K, Ni W, Corbett D, Yong VW, Power C. 2001. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 49:230-241.
48. Jourquin J, Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, Rivera S. 2003. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 18:1507-1517.
49. Justicia C, Panes J, Sole S, Cervera A, Deulofeu R, Chamorro A, Planas AM. 2003. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 23:1430-1440.
50. Kang T, Nagase H, Pei D. 2002. Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Cancer Res 62:675-681.
51. 2 as a trigger and NF-kappaB as a signal transducer. Thromb Haemost 90:528-537.
52. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. 1994. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 25:1794-1798.
53. Kuroiwa T, Ting P, Martinez H, Klatzo I. 1985. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol (Berl) 68:122-129.
54. Le DM, Besson A, Fogg DK, Choi KS, Waisman DM, Goodyer CG, Rewcastle B, Yong VW. 2003. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci 23:4034-4043.
55. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. 1994. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269:9352-9360.
56. Lee R, Kermani P, Teng KK, Hempstead BL. 2001. Regulation of cell survival by secreted proneurotrophins. Science 294:1945-1948.
57. Lee SR, Tsuji K, Lo EH. 2004. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24:671-678.
58. Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, Cheong JH, Ryu JH, Ko KH. 2003. Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide- stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41:15-24.
59. Lijnen HR. 2001. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86:324-333.
60. Lin TN, Sun SW, Cheung WM, Li F, Chang C. 2002. Dynamic changes in cerebral blood flow and angiogenesis after transient focal cerebral ischemia in rats. Evaluation with serial magnetic resonance imaging. Stroke 33:2985-2991.
61. Lo EH, Dalkara T, Moskowitz MA. 2003. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399-415.
62. Mannello F, Gazzanelli G. 2001. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 6:479-482.
63. Marti HH, Risau W. 1999. Angiogenesis in ischemic disease. Thromb Haemost 82(suppl 1):44-52.
64. Marti HJ, Bernaudin M, Bellail A, Schoch H, Euler M, Petit E, Risau W. 2000. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 156:965-976.
65. Martin-Villalba A, Hahne M, Kleber S, Vogel J, Falk W, Schenkel J, Krammer PH. 2001. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 8:679-686.
66. Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J, Schenkel J, Herdegen T, Debatin KM. 1999. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19:3809-3817.
67. Matsushita K, Wu Y, Qiu J, Lang-Lazdunski L, Hirt L, Waeber C, Hyman BT, Yuan J, Moskowitz MA. 2000. Fas receptor and neuronal cell death after spinal cord ischemia. J Neurosci 20:6879-6887.
68. Matyszak MK, Perry VH. 1996. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J Neuroimmunol 69:141-149.
69. Mayer AM, Hall M, Fay MJ, Lamar P, Pearson C, Prozialeck WC, Lehmann VK, Jacobson PB, Romanic AM, Uz T, Manev H. 2001. Effect of a short-term in vitro exposure to the marine toxin domoic acid on viability, tumor necrosis factor-alpha, matrix metalloproteinase-9 and superoxide anion release by rat neonatal microglia. BMC Pharmacol 1:7.
70. McCawley LJ, Matrisian LM. 2000. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6:149-156.
71. McCawley LJ, Matrisian LM. 2001. Tumor progression: defining the soil round the tumor seed. Curr Biol 11:R25-27.
72. Mentlein R, Ludwig R, Martensen I. 1998. Proteolytic degradation of Alzheimer's disease amyloid beta-peptide by a metalloproteinase from microglia cells. J Neurochem 70:721-726.
73. Mitsiades N, Poulaki V, Leone A, Tsokos M. 1999. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. J Natl Cancer Inst 91:1678-1684.
74. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. 2001. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61:577-581.
75. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. 2001a. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759-1766.
76. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J. 2001b. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762-2767.
77. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. 2003. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598-603.
78. Morita K, Itoh M, Saitou M, Ando-Akatsuka Y, Furuse M, Yoneda K, Imamura S, Fujimoto K, Tsukita S. 1998. Subcellular distribution of tight junction-associated proteins (occludin, ZO-1, ZO-2) in rodent skin. J Invest Dermatol 110:862-866.
79. Mun-Bryce S, Rosenberg GA. 1998a. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 274:R1203-1211.
80. Mun-Bryce S, Rosenberg GA. 1998b. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18:1163-1172.
81. Nagase H, Brew K. 2003. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem Soc Symp 201-212.
82. Nagase H, Woessner JF Jr. 1999. Matrix metalloproteinases. J Biol Chem 274:21491-21494.
83. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. 2000. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135-1149.
84. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW. 1999. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8464-8475.
85. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. 1999. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9:1441-1447.
86. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. 2003. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9:407-415.
87. Qiu J, Whalen MJ, Lowenstein P, Fiskum G, Fahy B, Darwish R, Aarabi B, Yuan J, Moskowitz MA. 2002. Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans. J Neurosci 22:3504-3511.
88. Risau W. 1997. Mechanisms of angiogenesis. Nature 386:671-674.
89. Rivera S, Ogier C, Jourquin J, Timsit S, Szklarczyk AW, Miller K, Gearing AJ, Kaczmarek L, Khrestchatisky M. 2002. Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur J Neurosci 15:19-32.
90. Rosenbaum DM, Gupta G, D'Amore J, Singh M, Weidenheim K, Zhang H, Kessler JA. 2000. Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia. J Neurosci Res 61:686-692.
91. Rosenberg GA. 1995. Matrix metalloproteinases in brain injury. J Neurotrauma 12:833-842.
92. Rosenberg GA. 2002a. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8:586-595.
93. Rosenberg GA. 2002b. Matrix metalloproteinases in neuroinflammation. Glia 39:279-291.
94. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. 1992. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576:203-207.
95. Rosenberg GA, Estrada EY, Dencoff JE. 1998. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29:2189-2195.
96. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A. 2001. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893:104-112.
97. Rosenberg GA, Mun-Bryce S. 2004. Matrix metalloproteinases in neuroinflammation and cerebral ischemia. Ernst Schering Res Found Workshop 1-16.
98. Rothenberg ML, Nelson AR, Hande KR. 1999. New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells 17:237-240.
99. Seeds NW, Siconolfi LB, Haffke SP. 1997. Neuronal extracellular proteases facilitate cell migration, axonal growth, and pathfinding. Cell Tissue Res 290:367-370.
100. Seo D-W, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei B-Y, Stetler-Stevenson WG. 2003. Timp-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell 114:171-180.
101. Sternlicht MD, Werb Z. 2001. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516.
102. Suryadevara R, Holter S, Borgmann K, Persidsky R, Labenz-Zink C, Persidsky Y, Gendelman HE, Wu L, Ghorpade A. 2003. Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 44:47-56.
103. Tan HK, Heywood D, Ralph GS, Bienemann A, Baker AH, Uney JB. 2003. Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol Cell Neurosci 22:98-106.
104. Vecil GG, Larsen PH, Corley SM, Herx LM, Besson A, Goodyer CG, Yong VW. 2000. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res 61:212-224.
105. Visse R, Nagase H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839.
106. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. 1998. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411-422.
107. Wallace JA, Alexander S, Estrada EY, Hines C, Cunningham LA, Rosenberg GA. 2002. Tissue inhibitor of metalloproteinase-3 is associated with neuronal death in reperfusion injury. J Cereb Blood Flow Metab 22:1303-1310.
108. Watson PM, Anderson JM, VanItallie CM, Doctrow SR. 1991. The tight-junction-specific protein ZO-1 is a component of the human and rat blood-brain barriers. Neurosci Lett 129:6-10.
109. Werb Z, Vu TH, Rinkenberger JL, Coussens LM. 1999. Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107:11-18.
110. Wetzel M, Rosenberg GA, Cunningham LA. 2003. Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur J Neurosci 18:1050-1060.
111. Wetzel M, Tibbitts J, Rosenberg GA, Cunningham LA. 2004. Vulnerability of mouse cortical neurons to doxorubicin-induced apoptosis is strain-dependent and is correlated with mRNAs encoding Fas, Fas-Ligand, and metalloproteinases. Apoptosis 9:649-656.
112. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-511.
113. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. 2000. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 275:31226-31232.
114. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, Bruggen N, Chopp M. 2000. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106:829-838.
115. Zhao H, Bernardo MM, Osenkowski P, Sohail A, Pei D, Nagase H, Kashiwagi M, Soloway PD, DeClerck YA, Fridman R. 2004. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation. J Biol Chem 279:8592-8601.